The Cbc Insider

Weight Loss By Injection

Weight Loss by Injection Options: Wegovy, Mounjaro & Saxenda – A Detailed Compare

In the fight against obesity, medical science has ushered in a new category of solutions: weight loss by injection. These treatments are designed not merely to suppress appetite but to recalibrate the hormonal pathways that govern metabolism, satiety, and insulin sensitivity. Among the most notable names are Wegovy, Mounjaro, and Saxenda—each representing a different chapter in the evolution of pharmacological weight control.

Why Weight Loss by Injection Is Gaining Popularity

Conventional diet and exercise regimens often fall short for those with metabolic resistance or chronic obesity. Weight loss by injection offers a tailored, clinically-supervised approach that bypasses the limitations of sheer willpower. These injectable therapies mimic naturally occurring hormones, reducing hunger signals and promoting fullness after smaller meals.

With rising obesity rates in the UK, the demand for evidence-based and sustainable weight loss options continues to surge. These injections have become a beacon of hope for individuals facing weight-related health conditions.

The Science Behind Injectable Weight Loss Treatments

These therapies harness the power of incretin mimetics—hormones released from the gut in response to food intake. By influencing receptors in the brain and pancreas, these hormones help regulate glucose metabolism and suppress hunger.

The three injectables under comparison—Wegovy, Mounjaro, and Saxenda—all act on these hormonal systems, albeit with nuanced variations in potency, duration, and dual-target engagement.

GLP-1 and GIP Explained: Hormonal Pathways That Matter

GLP-1 (Glucagon-like peptide-1) slows gastric emptying, promotes insulin release, and dampens appetite. Saxenda and Wegovy act exclusively on this pathway. Mounjaro, however, introduces a dual mechanism—targeting both GLP-1 and GIP (Glucose-dependent insulinotropic polypeptide), making it a pharmacological game-changer.

By enhancing both incretin signals, Mounjaro aims to double down on metabolic recalibration, offering higher efficacy in trials.

An Overview of Wegovy (Semaglutide)

Wegovy is a once-weekly GLP-1 receptor agonist derived from semaglutide. It was specifically developed for weight management and is approved for adults with a BMI ≥30, or ≥27 with weight-related comorbidities.

Clinical trials show Wegovy can lead to a 15% average reduction in body weight over 68 weeks, making it one of the most effective single-hormone injectable treatments available.

An Overview of Mounjaro (Tirzepatide)

Mounjaro is a next-generation injectable utilising dual hormone action—GLP-1 and GIP. Initially developed for type 2 diabetes management, it has demonstrated astonishing weight loss results, with up to 22% average body weight reduction in high-dose participants.

The dual receptor activation sets Mounjaro apart, allowing broader effects on fat metabolism and insulin control.

An Overview of Saxenda (Liraglutide)

Saxenda was one of the earliest GLP-1-based therapies approved for weight loss. Unlike its successors, it is administered daily rather than weekly. Saxenda’s effectiveness ranges between 5–10% body weight loss, typically achieved over 56 weeks.

Its shorter half-life and daily dosing may require more commitment, but it remains a viable entry point into medically-supervised weight loss.

Comparing Mechanisms of Action

  • Wegovy: Mimics GLP-1 to reduce hunger and slow digestion.
  • Mounjaro: Dual action on GLP-1 and GIP, enhancing appetite suppression and fat metabolism.
  • Saxenda: Daily GLP-1 mimic, influencing hunger centres and insulin regulation.

While Saxenda and Wegovy work on a single hormonal axis, Mounjaro’s dual engagement provides enhanced metabolic recalibration.

Efficacy Outcomes: Clinical Trial Results at a Glance

  • Mounjaro: Up to 22% weight loss in 72 weeks (SURMOUNT-1 Trial).
  • Wegovy: 14.9–16% weight reduction in 68 weeks (STEP 1 Study).
  • Saxenda: 8–10% average loss in 56 weeks (SCALE Study).

Clearly, Mounjaro leads in raw efficacy, but availability and individual tolerability must be factored into any decision.

Dosing Schedules and Administration Differences

  • Saxenda: Daily injection, titrated up to 3.0mg.
  • Wegovy: Weekly injection, up to 2.4mg.
  • Mounjaro: Weekly injection, up to 15mg.

Weekly regimens (Wegovy, Mounjaro) offer greater convenience and are generally preferred by patients for long-term adherence.

Side Effects and Risk Profiles

  • Common Side Effects: Nausea, diarrhoea, constipation, headache.
  • Rare Risks: Pancreatitis, gallbladder issues, potential thyroid tumours (in animal studies).

Mounjaro’s dual mechanism may increase gastrointestinal side effects, though these often subside with dose adjustment. Monitoring by healthcare providers is essential for all injectable treatments.

Suitability for Different BMI and Health Conditions

  • Saxenda: BMI ≥30 or ≥27 with comorbidities.
  • Wegovy: BMI ≥30 or ≥27 with health issues like hypertension or sleep apnoea.
  • Mounjaro: Currently approved for diabetes, but weight loss indications are expanding globally.

Medical history, comorbidities, and treatment goals determine which injection suits each patient. Some may begin with Saxenda, then transition to Wegovy or Mounjaro for greater effect.

Accessibility: NHS vs Private Prescriptions

Saxenda and Wegovy are available via select NHS weight management services, though access is limited and waiting lists are long. Mounjaro remains available primarily through private clinics in the UK.

Private clinics offer faster access, customised plans, and consistent monitoring—benefits that appeal to patients ready for transformative change.

Lifestyle Integration and Support Needs

Weight loss by injection is not a standalone cure. Behavioural counselling, nutrition planning, and physical activity are crucial for long-term success.

Clinics offering these injectables often integrate lifestyle support services. This holistic model improves adherence, helps manage side effects, and fosters sustainable weight management.

Long-Term Success: Sustainability After Injection Ends

Studies suggest that many patients regain some weight after stopping injections, particularly if lifestyle changes are not maintained. The key to long-term success lies in continuing healthy behaviours developed during treatment.

Support systems, follow-ups, and psychological counselling enhance post-treatment durability.

Costs and Considerations for UK Patients

  • Saxenda: Approx. £150–£250 per month.
  • Wegovy: £200–£300 monthly (private).
  • Mounjaro: £250–£400 depending on dosage.

Cost, while significant, must be weighed against long-term healthcare savings from reduced comorbidity risks. For many, it is a worthwhile investment in quality of life and disease prevention.

Final Verdict: Which Weight Loss Injection Fits Best?

Each treatment has unique strengths:

  • Choose Saxenda if you want a trusted, lower-dose, daily option to begin your journey.
  • Choose Wegovy for weekly convenience and high efficacy in a single-hormone pathway.
  • Choose Mounjaro if you're aiming for transformative weight loss with the latest dual-action science.

Ultimately, the best choice for weight loss by injection depends on medical history, treatment goals, and access. Consulting with a qualified healthcare provider ensures a safe, effective, and personalised path to healthier living.